PMID- 29523769
OWN - NLM
STAT- MEDLINE
DCOM- 20180924
LR  - 20211204
IS  - 1470-8752 (Electronic)
IS  - 0300-5127 (Print)
IS  - 0300-5127 (Linking)
VI  - 46
IP  - 2
DP  - 2018 Apr 17
TI  - The mechanistic target of rapamycin (mTOR) and the silent mating-type information 
      regulation 2 homolog 1 (SIRT1): oversight for neurodegenerative disorders.
PG  - 351-360
LID - 10.1042/BST20170121 [doi]
AB  - As a result of the advancing age of the global population and the progressive 
      increase in lifespan, neurodegenerative disorders continue to increase in 
      incidence throughout the world. New strategies for neurodegenerative disorders 
      involve the novel pathways of the mechanistic target of rapamycin (mTOR) and the 
      silent mating-type information regulation 2 homolog 1 (Saccharomyces cerevisiae) 
      (SIRT1) that can modulate pathways of apoptosis and autophagy. The pathways of 
      mTOR and SIRT1 are closely integrated. mTOR forms the complexes mTOR Complex 1 
      and mTOR Complex 2 and can impact multiple neurodegenerative disorders that 
      include Alzheimer's disease, Huntington's disease, and Parkinson's disease. SIRT1 
      can control stem cell proliferation, block neuronal injury through limiting 
      programmed cell death, drive vascular cell survival, and control clinical 
      disorders that include dementia and retinopathy. It is important to recognize 
      that oversight of programmed cell death by mTOR and SIRT1 requires a fine degree 
      of precision to prevent the progression of neurodegenerative disorders. 
      Additional investigations and insights into these pathways should offer effective 
      and safe treatments for neurodegenerative disorders.
CI  - (c) 2018 The Author(s). Published by Portland Press Limited on behalf of the 
      Biochemical Society.
FAU - Maiese, Kenneth
AU  - Maiese K
AD  - Cellular and Molecular Signaling, Newark, NJ 07101, U.S.A. wntin75@yahoo.com.
LA  - eng
GR  - R01 NS053946/NS/NINDS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180309
PL  - England
TA  - Biochem Soc Trans
JT  - Biochemical Society transactions
JID - 7506897
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Cell Survival
MH  - Humans
MH  - Neurodegenerative Diseases/*metabolism
MH  - Saccharomyces cerevisiae/metabolism
MH  - Sirtuin 1/*metabolism
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5906169
MID - NIHMS954527
OTO - NOTNLM
OT  - cell death
OT  - molecular disease
OT  - signaling
COIS- Competing Interests The Author declares that there are no competing interests 
      associated with the manuscript.
EDAT- 2018/03/11 06:00
MHDA- 2018/09/25 06:00
PMCR- 2019/04/17
CRDT- 2018/03/11 06:00
PHST- 2017/11/25 00:00 [received]
PHST- 2018/02/11 00:00 [revised]
PHST- 2018/02/15 00:00 [accepted]
PHST- 2018/03/11 06:00 [pubmed]
PHST- 2018/09/25 06:00 [medline]
PHST- 2018/03/11 06:00 [entrez]
PHST- 2019/04/17 00:00 [pmc-release]
AID - BST20170121 [pii]
AID - 10.1042/BST20170121 [doi]
PST - ppublish
SO  - Biochem Soc Trans. 2018 Apr 17;46(2):351-360. doi: 10.1042/BST20170121. Epub 2018 
      Mar 9.